Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Oct;38(10):2287–2295. doi: 10.1128/aac.38.10.2287

Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.

N Rastogi 1, K S Goh 1, E L Wright 1, W W Barrow 1
PMCID: PMC284732  PMID: 7840559

Abstract

Previously established radiometric techniques were used to assess the effectiveness of combined antimicrobial drug-inhibitory drug (drug-inhibitor) treatment on two clinical isolates of the Mycobacterium avium complex representing three colony variants: smooth opaque (dome) (SmO), smooth transparent (SmT), and rough (Rg). All variants were identified as members of the M. avium complex; however, only the SmT colony type of strain 373 possessed characteristic serovar-specific glycopeptidolipid (GPL) antigens. MICs, determined radiometrically, of drugs with the potential to inhibit the biosynthesis of GPL antigens or other cell envelope constituents were similar for all strains. These drugs included cerulenin, N-carbamyl-DL-phenylalanine, N-carbamyl-L-isoleucine, trans-cinnamic acid, ethambutol, 1-fluoro-1-deoxy-beta-D-glucose, 2-deoxy-D-glucose, and m-fluoro-phenylalanine. The MICs of the antimicrobial drugs amikacin, sparfloxacin, and clarithromycin varied, but overall the MICs for the SmO variant were the lowest. Radiometric assessment of drug-inhibitor combinations by using established x/y determinations revealed enhanced activity when either ethambutol or cerulenin were used in combination with all antimicrobial agents for all variants except the Rg variant of strain 424, for which ethambutol was not effective. Enhanced activity with amino acid analogs was observed with the Rg colony variants of strains 373 and 424. Two potential sites for drug targeting were identified: fatty acid synthesis, for all strains assayed, and peptide biosynthesis, particularly for Rg colony variants that possess previously identified phenylalanine-containing lipopeptides as potential targets for future drug development.

Full text

PDF
2287

Images in this article

2289Image
on p.2289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrow W. W., Brennan P. J. Isolation in high frequency of rough variants of Mycobacterium intracellulare lacking C-mycoside glycopeptidolipid antigens. J Bacteriol. 1982 Apr;150(1):381–384. doi: 10.1128/jb.150.1.381-384.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barrow W. W. Contributing factors of pathogenesis in the Mycobacterium avium complex. Res Microbiol. 1991 May;142(4):427–433. doi: 10.1016/0923-2508(91)90115-q. [DOI] [PubMed] [Google Scholar]
  3. Barrow W. W., Ullom B. P., Brennan P. J. Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria. J Bacteriol. 1980 Nov;144(2):814–822. doi: 10.1128/jb.144.2.814-822.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barrow W. W., Wright E. L., Goh K. S., Rastogi N. Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium. Antimicrob Agents Chemother. 1993 Apr;37(4):652–661. doi: 10.1128/aac.37.4.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barrow W. W., de Sousa J. P., Davis T. L., Wright E. L., Bachelet M., Rastogi N. Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium. Infect Immun. 1993 Dec;61(12):5286–5293. doi: 10.1128/iai.61.12.5286-5293.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Belisle J. T., Brennan P. J. Molecular basis of colony morphology in Mycobacterium avium. Res Microbiol. 1994 Mar-Apr;145(3):237–242. doi: 10.1016/0923-2508(94)90024-8. [DOI] [PubMed] [Google Scholar]
  7. Belisle J. T., McNeil M. R., Chatterjee D., Inamine J. M., Brennan P. J. Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of Mycobacterium avium. J Biol Chem. 1993 May 15;268(14):10510–10516. [PubMed] [Google Scholar]
  8. Brennan P. J., Souhrada M., Ullom B., McClatchy J. K., Goren M. B. Identification of atypical mycobacteria by thin-layer chromatography of their surface antigens. J Clin Microbiol. 1978 Oct;8(4):374–379. doi: 10.1128/jcm.8.4.374-379.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Brownback P. E., Barrow W. W. Modified lymphocyte response to mitogens after intraperitoneal injection of glycopeptidolipid antigens from Mycobacterium avium complex. Infect Immun. 1988 May;56(5):1044–1050. doi: 10.1128/iai.56.5.1044-1050.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  11. David H. L. Basis for lack of drug susceptibility of atypical mycobacteria. Rev Infect Dis. 1981 Sep-Oct;3(5):878–884. doi: 10.1093/clinids/3.5.878. [DOI] [PubMed] [Google Scholar]
  12. Etzkorn E. T., Aldarondo S., McAllister C. K., Matthews J., Ognibene A. J. Medical therapy of Mycobacterium avium-intracellulare pulmonary disease. Am Rev Respir Dis. 1986 Sep;134(3):442–445. doi: 10.1164/arrd.1986.134.3.442. [DOI] [PubMed] [Google Scholar]
  13. Hawkins C. C., Gold J. W., Whimbey E., Kiehn T. E., Brannon P., Cammarata R., Brown A. E., Armstrong D. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Aug;105(2):184–188. doi: 10.7326/0003-4819-105-2-184. [DOI] [PubMed] [Google Scholar]
  14. Heifets L. B., Iseman M. D., Lindholm-Levy P. J. Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. Drugs Exp Clin Res. 1987;13(9):529–538. [PubMed] [Google Scholar]
  15. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 1993 Nov;37(11):2364–2370. doi: 10.1128/aac.37.11.2364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hoffner S. E., Kratz M., Olsson-Liljequist B., Svenson S. B., Källenius G. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex. J Antimicrob Chemother. 1989 Sep;24(3):317–324. doi: 10.1093/jac/24.3.317. [DOI] [PubMed] [Google Scholar]
  17. Hooper L. C., Johnson M. M., Khera V. R., Barrow W. W. Macrophage uptake and retention of radiolabeled glycopeptidolipid antigens associated with the superficial L1 layer of Mycobacterium intracellulare serovar 20. Infect Immun. 1986 Oct;54(1):133–141. doi: 10.1128/iai.54.1.133-141.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother. 1987 Nov;31(11):1697–1702. doi: 10.1128/aac.31.11.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nomura S., Horiuchi T., Omura S., Hata T. The action mechanism of cerulenin. I. Effect of cerulenin on sterol and fatty acid biosynthesis in yeast. J Biochem. 1972 May;71(5):783–796. doi: 10.1093/oxfordjournals.jbchem.a129827. [DOI] [PubMed] [Google Scholar]
  20. Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev. 1976 Sep;40(3):681–697. doi: 10.1128/br.40.3.681-697.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pourshafie M., Ayub Q., Barrow W. W. Comparative effects of Mycobacterium avium glycopeptidolipid and lipopeptide fragment on the function and ultrastructure of mononuclear cells. Clin Exp Immunol. 1993 Jul;93(1):72–79. doi: 10.1111/j.1365-2249.1993.tb06499.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ramasesh N., Wright E. L., Barrow W. W. Cell-free system responsible for internal radiolabeling of glycopeptidolipids of the Mycobacterium avium complex. Infect Immun. 1992 Jan;60(1):308–311. doi: 10.1128/iai.60.1.308-311.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., David H. L. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents? Antimicrob Agents Chemother. 1981 Nov;20(5):666–677. doi: 10.1128/aac.20.5.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rastogi N., Goh K. S. Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine. Antimicrob Agents Chemother. 1990 Nov;34(11):2061–2064. doi: 10.1128/aac.34.11.2061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rastogi N., Goh K. S., David H. L. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res Microbiol. 1989 Jul-Aug;140(6):405–417. doi: 10.1016/0923-2508(89)90016-8. [DOI] [PubMed] [Google Scholar]
  26. Rastogi N., Goh K. S., David H. L. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother. 1990 May;34(5):759–764. doi: 10.1128/aac.34.5.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Rastogi N., Goh K. S., Guillou N., Labrousse V. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs? Zentralbl Bakteriol. 1992 Dec;277(4):474–484. doi: 10.1016/s0934-8840(11)80472-x. [DOI] [PubMed] [Google Scholar]
  28. Rulong S., Aguas A. P., da Silva P. P., Silva M. T. Intramacrophagic Mycobacterium avium bacilli are coated by a multiple lamellar structure: freeze fracture analysis of infected mouse liver. Infect Immun. 1991 Nov;59(11):3895–3902. doi: 10.1128/iai.59.11.3895-3902.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Siddiqi S. H., Libonati J. P., Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 1981 May;13(5):908–912. doi: 10.1128/jcm.13.5.908-912.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Takayama K., Kilburn J. O. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother. 1989 Sep;33(9):1493–1499. doi: 10.1128/aac.33.9.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Tereletsky M. J., Barrow W. W. Postphagocytic detection of glycopeptidolipids associated with the superficial L1 layer of Mycobacterium intracellulare. Infect Immun. 1983 Sep;41(3):1312–1321. doi: 10.1128/iai.41.3.1312-1321.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Woodbury J. L., Barrow W. W. Radiolabelling of Mycobacterium avium oligosaccharide determinant and use in macrophage studies. J Gen Microbiol. 1989 Jul;135(7):1875–1884. doi: 10.1099/00221287-135-7-1875. [DOI] [PubMed] [Google Scholar]
  33. Wright E. L., Barrow W. W. Inhibition of glycopeptidolipid synthesis resulting from treatment of Mycobacterium avium with 2-deoxy-D-glucose. Res Microbiol. 1991 Jun;142(5):597–608. doi: 10.1016/0923-2508(91)90193-e. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES